TY  - JOUR
A1  - Yang, Xiaoping
A1  - Darko, Kwame Oteng
A1  - Huang, Yanjun
A1  - He, Caimei
A1  - Yang, Huansheng
A1  - He, Shanping
A1  - Li, Jianzhong
A1  - Li, Jian
A1  - Hocher, Berthold
A1  - Yin, Yulong
T1  - Resistant starch regulates gut microbiota
BT  - structure, biochemistry and cell signalling
JF  - Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry and pharmacology
N2  - Starch is one of the most popular nutritional sources for both human and animals. Due to the variation of its nutritional traits and biochemical specificities, starch has been classified into rapidly digestible, slowly digestible and resistant starch. Resistant starch has its own unique chemical structure, and various forms of resistant starch are commercially available. It has been found being a multiple-functional regulator for treating metabolic dysfunction. Different functions of resistant starch such as modulation of the gut microbiota, gut peptides, circulating growth factors, circulating inflammatory mediators have been characterized by animal studies and clinical trials. In this mini-review, recent remarkable progress in resistant starch on gut microbiota, particularly the effect of structure, biochemistry and cell signaling on nutrition has been summarized, with highlights on its regulatory effect on gut microbiota.
KW  - Resistant starch
KW  - Gut microbiota
KW  - Nutrition
Y1  - 2017
U6  - https://doi.org/10.1159/000477386
SN  - 1015-8987
SN  - 1421-9778
VL  - 42
IS  - 1
SP  - 306
EP  - 318
PB  - Karger
CY  - Basel
ER  - 
TY  - JOUR
A1  - Tao, Ting
A1  - Su, Qiongli
A1  - Xu, Simeng
A1  - Deng, Jun
A1  - Zhou, Sichun
A1  - Zhuang, Yu
A1  - Huang, Yanjun
A1  - He, Caimei
A1  - He, Shanping
A1  - Peng, Mei
A1  - Hocher, Berthold
A1  - Yang, Xiaoping
T1  - Down-regulation of PKM2 decreases FASN expression in bladder cancer cells through AKT/mTOR/SREBP-1c axis
JF  - Journal of cellular physiology
N2  - Fatty acid synthase (FASN) catalyzing the terminal steps in the de novo biogenesis of fatty acids is correlated with low survival and high disease recurrence in patients with bladder cancer. Pyruvate kinase M2 (PKM2) regulates the final step of glycolysis levels and provides a growth advantage to tumors. However, it is unclear whether the change of PKM2 has an effect on FASN and what is the mechanisms underlying. Here we describe a novel function of PKM2 in control of lipid metabolism by mediating transcriptional activation of FASN, showing the reduced expression of sterol regulatory element binding protein 1c (SREBP-1c). We first discovered that PKM2 physically interacts with the SREBP-1c using biochemical approaches, and downregulation of PKM2 reduced the expression of SREBP-1c by inactivating the AKT/mTOR signaling pathway, which in turn directly suppressed the transcription of major lipogenic genes FASN to reduce tumor growths. Furthermore, either PKM2 inhibitor-Shikonin or FASN inhibitor-TVB-3166 alone induced a strong antiproliferative and anticolony forming effect in bladder cancer cell line. The combination of both inhibitors exhibits a super synergistic effect on blocking the bladder cancer cells growth. It provides a new target and scientific basis for the treatment of bladder cancer.
KW  - bladder cancer cells
KW  - FASN
KW  - p-AKT
KW  - PKM2
KW  - p-mTOR
KW  - SREBP-1c
Y1  - 2018
U6  - https://doi.org/10.1002/jcp.27129
SN  - 0021-9541
SN  - 1097-4652
VL  - 234
IS  - 3
SP  - 3088
EP  - 3104
PB  - Wiley
CY  - Hoboken
ER  -